Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 3/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924360 | 1.00 | GAA (0.38) | GAALMNACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10447820 | 0.80 | — | — | |
| SCHEMBL5924537 | 0.80 | SORT1 (0.30) | — | |
| SCHEMBL5924293 | 0.80 | ROCK2 (0.32) | — | |
| SCHEMBL10447580 | 0.72 | SMN1; SMN2 (0.34) | MEN1KMT2A | |
| SCHEMBL10326864 | 0.72 | PRCP (0.44) | GAAHTTPAX8VDRPRCP | |
| SCHEMBL6438511 | 0.72 | ITGB3 (0.41) | GAALMNACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2863781 | 0.72 | ITGB3 (0.41) | GAALMNACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3228085 | 0.71 | GAA (0.36) | GAALMNACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31692716 | 0.71 | GAA (0.36) | GAALMNACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160357901-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160357901-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2016-12-08 | — | — | US | disclosed |
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2013-10-31 | — | — | US | disclosed |
| US-5061808-A | 2-oxo-1-pyrrolidine carboxylic acid esters | WARNER-LAMBERT COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| US-4876343-A | Process for statine and statine analogs | WARNER-LAMBERT COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | SERBP1, PAIP1, DNPEP | GAA 3652/4885LMNA 3937/4885CYP3A4 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.